
MBF Healthcare Acquisition Corp.
Acquisition of
Critical Homecare Solutions

June 24, 2008



Forward Looking Statements

This presentation may include statements regarding anticipated and future developments that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contained in forward-looking statements due to a number of factors including the risk factors detailed in our filings with the Securities and Exchange Commission. Additionally, market data included in this presentation reflects Company estimates unless otherwise indicated.

Our financial guidance is as of the date indicated and MBF Healthcare Acquisition Corp. (“MBH”) and Critical Homecare Solutions Holdings, Inc. (“CHS” and together with MBH, the “Company”) undertake no obligation to revise or update any such forward-looking statements or Company estimates to reflect events or circumstances after such date, or after the date of this presentation.

Without limiting the foregoing, the inclusion of the financial projections in this presentation should not be regarded as an indication that CHS’ or MBH’s boards of directors or any other recipient of the information considered, or now considers, them to be a reliable prediction of the future results. The financial projections were not prepared with a view towards public disclosure or with a view to complying with the published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants with respect to prospective financial information or with U.S. generally accepted accounting principles. Neither CHS’ or MBH’s independent auditors, nor any other independent accountants, have compiled, examined or performed any procedures with respect to the financial projections, nor have they expressed any opinion or any other form of assurance on such information or its achievability. Although the financial projections were prepared based on assumptions and estimates that the Company’s management believes are reasonable, the Company provides no assurance that the assumptions made in preparing the financial projections will prove accurate or that actual results will be consistent with these financial projections. Projections of this type involve significant risks and uncertainties, should not be read as guarantees of future performance or results and will not necessarily be accurate indicators of whether or not such results will be achieved.

Agenda

- I. Executive Summary
- II. Overview of Critical Homecare Solutions
- III. Financial Overview
- IV. Summary
- V. Questions & Answers

I. Executive Summary

Additional Information & Participants in Solicitation

Additional Information and Where to Find It

- On June 3, 2008, MBH filed an amended preliminary proxy statement concerning the proposed transaction, which is subject to review by the Securities and Exchange Commission. MBH stockholders and other interested persons are urged to read the proxy statement and other relevant materials when they become available as they will contain important information about MBH, CHS and the proposed transaction. Such persons can also read MBH's final prospectus dated April 17, 2007, for a description of the security holdings of the MBH officers and directors and their respective interests in the successful consummation of the proposed transaction. The definitive proxy statement will be mailed to stockholders as of a record date to be established for voting on the proposed transaction. MBH stockholders will be able to obtain a free copy of the definitive proxy statement through the SEC's internet website (<http://www.sec.gov>). Copies of the proxy statement can also be obtained, without charge, by directing a request to MBF Healthcare Acquisition Corp., 121 Alhambra Plaza, Suite 1100, Coral Gables, FL 33134.

Participants in Solicitation

- MBH and its directors and executive officers and CHS and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of MBH stock in respect of the proposed transaction. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement relating to the proposed transaction and MBH's Annual Report on Form 10-K for its fiscal year ended December 31, 2007 when they become available.

CHS Investment Considerations

- Founded in 2006 by five senior homecare executives with over 100 years of combined healthcare experience
- Phenomenal growth from inception with pro forma revenue quadrupling to \$203.4mm in 2007 from \$49.8mm in 2006
- 20% same store pre-corporate EBITDA⁽¹⁾ (CAGR 2005 to 2007)
- Business successfully operated and high margins sustained, while pursuing acquisition growth strategy
- Well positioned as a consolidator in extremely fragmented \$5.5 billion infusion therapy market
- Experienced management team in acquiring and consolidating homecare companies with over 70 homecare acquisitions in the last 13 years

Note:

1 EBITDA excludes stock options expense

CHS Executive Management Team Members

Name	Position	Years of Experience	Previous Experience
Robert Cucuel	President, CEO	24	<ul style="list-style-type: none"> • President & CEO of Air Products Healthcare, a \$325mm provider of Respiratory & Infusion Therapy • Founder, President & CEO of American Homecare Supply, a \$130mm Home Infusion and Respiratory Therapy company • Senior level positions at American Home Patient, Home Health Corporation of America, Home Nutritional Services, HILL-ROM, American Hospital Supply
MJ Graves CPA	CFO	24	<ul style="list-style-type: none"> • Independent consultant to American Homecare Supply and Air Products Healthcare in financial and operational capacities • CFO positions with Superior Renal Care and Stadtlander Drug Distribution • 9 years of public accounting with Arthur Andersen
Colleen Lederer	SVP, Professional Services	30	<ul style="list-style-type: none"> • VP of Professional Services and Compliance for Home Health Corporation of America • Founding partner and owner of a home health staffing and consulting agency
Nitin Patel	SVP, Operations	25	<ul style="list-style-type: none"> • Senior purchasing and operating roles at Air Products Healthcare and American Homecare Supply • Senior operational roles at American Home Patient, Home Health Corporation of America and Home Nutritional Services
Joey Ryan CPA	SVP, Compliance & Reimbursement	21	<ul style="list-style-type: none"> • Senior Vice President of Reimbursement and Compliance for Air Products Healthcare and American Homecare Supply • Former owner of a healthcare reimbursement and compliance consulting company

Why Home Infusion?

All payors seek the most cost effective quality settings, which includes home based community care

	Acquisition Opportunities	Positive Regulatory & Reimbursement Outlook	Lack of Privately Held Platforms	Favorable Organic Growth	Diversified Payor Mix	Low CapEx
Home Nursing	✓	✓		✓		✓
Home Respiratory	✓		✓	✓		
Home Durable Medical Equipment	✓		✓	✓		
Home Infusion	✓	✓	✓	✓	✓	✓

II. Overview of Critical Homecare Solutions

Overview of Critical Homecare Solutions

Local business model serving 16,000 patients with 450 payor relationships

Infusion Therapy

Business Description

- Delivers complex intravenous pharmaceutical products and corresponding clinical support services to patients

Key Therapies / Services

- Antibiotic Therapy
- Total Parenteral Nutrition
- Enteral Nutrition

Locations


- 35 in 15 states

Operating Statistics

- > 400,000 infusion pharmaceuticals, biopharmaceuticals and related services and equipment

Financial Performance¹

- PF 2007A revenue of \$203.4mm
- PF 2007A post-corporate EBITDA of \$36.7mm
- Q1 2008A revenue of \$54.7mm
- Q1 2008A post-corporate EBITDA of \$10.25mm



Note:


¹ Pro forma numbers reflect the acquisitions completed through December 31, 2007 as if they had been completed as of January 1, 2007. Wilcox acquisition is not included for Q1 2008A financials.

Evolution of Critical Homecare Solutions

Founded in August 2006, CHS has become one of the largest home infusion players

- Incorporated in Delaware on August 8, 2006
- Started operations with the acquisitions of Specialty Pharma and New England Home Therapies
- Demonstrated ability to integrate both large and small providers

Evolution of CHS




Home Infusion Overview

Home infusion therapy includes subcutaneous, intravenous and epidural administration of medications for treatment of a broad range of medical conditions

Services

- Home infusion services in a patient's home or in an ambulatory infusion centers
- In-home delivery of pharmaceuticals
- 24-hour nursing and pharmacy availability
- Patient consultations, education and training
- Reimbursement, billing and collection services
- Monitoring treatment plans and progress reports to physicians and managed care organizations
- Biomedical services for equipment

Industry Framework



Home Infusion Market


CHS is one of the 4 largest providers in highly fragmented space and the largest privately owned provider

Of the 75% “Others” category listed below, approximately 15% have revenues greater than \$20mm¹

Industry Dynamics

- Consolidation opportunity
- Scarcity of infusion platform with scale
- Top infusion industry providers recently acquired
 - Option Care / Walgreens
 - Coram / Apria
 - Critical Care Systems / MedCo
- Top providers under definitive acquisition agreements
 - CuraScript / Walgreens – 6/10/08
 - Apria / Blackstone Group affiliate – 6/18/08

Highly Fragmented Market^{1, 2}



1 Wall Street estimates and company estimates

2 Comprised of approximately 1,200 US providers; small, individually-owned or closely-held local operations to hospital-based providers and national providers

3 Apria completed purchase of Coram on December 3, 2007


4 Walgreens completed purchase of Option Care on August 20, 2007

5 Medco announced acquisition of Critical Care Systems on November 1, 2007

Market Opportunities

Why is the infusion industry the right fit?

- Fragmented industry (75% independently owned)
- Favorable industry organic growth rates (6%-7% annually)
- Favorable, diversified payor mix
 - Managed care (70% of IV mix)
 - Medicare (18% of IV mix)
 - Industry: 60%-65% Managed care, 12%-17% Medicare¹
- Medicare infusion drug coverage opportunity
 - H.R. 2567 (44 co-sponsors)
 - Provides coverage for home infusion therapies
 - One of the only markets where Medicare is a potential positive
- Market expansion with Medicare Advantage plans
 - Only 17% of beneficiaries enrolled
- Pipeline of infused or injectable drugs for over 400 therapies
- Value proposition to all payors and patients
- \$1B expansion opportunity if care setting is changed to home¹



Source: Morrison Informatics Study of June 2007 (Cost of administering Vancomycin 1gm IV q12h)


Note:

¹ Per company estimates

Attractive Payor Mix


Attractive payor mix with approximately 450 payor relationships

Consolidated Payor Mix



Relationships with approximately 450 payors, including insurers, managed care organizations and government payors

Home Infusion Payor Mix



No single managed care payor represents more than 8% of infusion revenue

Organic Growth Strategy

Focus on High Value Infusion Therapies

- Anti-infective Therapy, Total Parenteral Nutrition, and Enteral Nutrition (Tier I)
- 53% of infusion business comprised of these three therapies
- Continued improvement and focus on the Tier I therapy mix

Operate Local Clinical Model

- Customize care to local market and demands
- Homecare is a local business given the industry's highly fragmented provider base

Target Local and Regional Sources

- Market share gains achieved at the local level
- Relationship business with referral sources

Expand Payor Relationships

- Leverage payor relationships to regional / national
- Synergy gains with new acquisitions
- Over 450 payors

Acquisition Growth Strategy

Continue to execute on highly successful business strategy that emphasizes acquisition growth

- Consistently apply disciplined approach to each opportunity
- Acquire leading independent home infusion providers in contiguous and other strategic markets
- Efficiently integrate targets into operations
 - Leverage purchasing scale
 - Increase productivity with CPR & MIS platform
- Adopt target's best practices to realize additional operational efficiencies
- Acquire 4-6 targets per year
- 75% of industry comprised of independents

Highlights of Acquisition Capabilities

Known as the preferred industry consolidator


- Deal sourcing
 - Overall industry contacts, knowledge of competitive landscape and premier providers
 - 5 of first 9 deals, CHS was the only buyer
- Acquisition criteria
 - Location
 - Product and payor mix
 - Size
 - Local management
 - Quality of receivables
 - Growth opportunities
- Due diligence effort
 - Detailed work plan covering areas such as risk management, compliance, finance, accounts receivable, clinical, regulatory, operations, reimbursement controls, contracts, insurance, etc.

Attractive Expansion Opportunities

Target leading home infusion providers located in attractive markets adjacent to existing businesses

Approximately 2/3 of the industry's expansion opportunities lie in existing presence and targeted growth areas

Target Markets



Current Acquisition Pipeline

Deep pipeline of attractive acquisitions opportunities

Goal to close four to six deals per year


Target	Status	Revenue (\$mm)	EBITDA (\$mm)	Status
1	Ongoing	8	2	–
2	Ongoing	9	3	–
3	Ongoing	8	2	LOI
4	Ongoing	9	1	–
5	Ongoing	4	1	–
6	Ongoing	17	2	DPA
7	Ongoing	8	1	–
8	Ongoing	11	2	–
9	Ongoing	34	13	–
10	Ongoing	12	3	–
11	Ongoing	15	3	–
12	Ongoing	60	7	–
13	Ongoing	3	1	–
14	Ongoing	4	1	–
15	Ongoing	60	8	–
Total		\$262m	\$50m	

III. Financial Overview


Strong Financial Performance

Achieved strong growth and profitability through the successful implementation of its business strategy

Pro Forma Revenue¹ (\$ millions)



Pro Forma Pre-Corporate EBITDA^{1,2,3} (\$ millions)




- 1 Pro forma for all acquisitions completed through 12/31/07; EBITDA excludes stock options expense
- 2 Excludes \$0.4 million and \$4.6 million of corporate charges in 2006 and 2007, respectively
- 3 Figures inside columns represent pro forma adjusted EBITDA margins

Strong Operating Performance

Relative to the comparable companies, EBITDA margins are higher due to concentration on high margin infusion products

Management believes these EBITDA margins are sustainable



Notes:

- 1 Twelve months ended 12/31/07; post-corporate EBITDA Q1 2008A at 18.6%
- 2 Six months ended 06/30/07
- 3 Apria purchased Coram for ~\$350 million, approximately 0.7x Coram's 2007E revenue and 15.5x its run-rate EBITDA without synergies; Wall Street Research; EBITDA margin for the nine months ended 9/30/07
- 4 Management projections for 2007E

Financial Summary

(\$ mm)	Historical		PF2007 ¹				Year Ending
	Year Ending December 31,		Q1 2007A	Q2 2007A	Q3 2007A	Q4 2007A	December 31,
	2005A ¹	2006A ¹					PF2007A ¹
Revenue	173.0	187.7	49.8	48.4	51.2	54.0	203.4
Gross Profit	86.6	92.6	24.0	25.3	26.1	27.8	103.2
EBITDA, Pre-Corporate 1	28.7	36.2	9.0	9.8	10.4	12.1	41.3
EBITDA, Post-Corporate 1	28.7	35.7	8.2	8.7	9.1	10.7	36.7
Capital Expenditures	2.3	3.7	0.9	0.8	0.7	0.7	3.1
EBITDA less CapEx	26.4	32.0	7.3	7.9	8.4	10.0	33.6
<i>% of Revenue</i>							
Gross Margin	50.0%	49.3%	48.2%	52.2%	51.0%	51.5%	50.7%
EBITDA, Pre-Corporate 1	16.6%	19.3%	18.1%	20.3%	20.2%	22.4%	20.3%
Y-o-Y Growth, Net Revenue	13.6%	8.5%					8.3%

¹ The pro forma income statements reflect each acquisition as if it had been completed as of January 1, 2005. EBITDA, as referenced above, represents as adjusted EBITDA. Pro forma adjustments in the related determination have been determined in accordance with the definition provided by the Company's first and second lien secured creditors less the write off of certain stock issuance costs, and may not conform to the SEC's regulations regarding pro forma adjustments

Financial Summary – 1st Quarter Results

(\$ mm)	PF Q1 2007A	Q1 2008A	\$ Change	% Change
Revenue	49.8	54.7	4.9	9.8%
Gross Profit	24.0	27.7	3.7	15.4%
EBITDA, Pre-Corporate 1	9.0	11.7	2.7	30.0%
EBITDA, Post-Corporate 1	8.2	10.2	2.0	24.4%
Capital Expenditures	0.9	0.5	(0.4)	(44.4)%
EBITDA less CapEx	7.3	9.7	2.4	32.9%
<i>% of Revenue</i>				
<i>Gross Margin</i>	48.2%	50.6%		
<i>EBITDA, Pre-Corporate 1</i>	18.1%	21.3%		
<i>Y-o-Y Growth, Net Revenue</i>		9.8%		

Estimated Sources and Uses

Assumes 100% approval

<u>Sources</u>		<u>Uses</u>	
Term Loan B	\$140.0	Purchase Price of Equity	\$420.0
Subordinated Debt	40.0	Estimated Total Fees	15.0
Equity Issuance to Sellers	35.0	Working Capital	10.0
Equity Commitment	50.0		
Estimated SPAC Equity	180.0		
Total Sources	\$445.0	Total Uses	\$445.0

Capital structure designed to accommodate the Company's acquisition strategy

Future acquisitions funded by:

- Free cash flow
- \$20mm first lien delayed draw term loan
- \$25mm first lien revolver

\$ in millions

Source: Company filings and Company Management

Note: Estimated sources and uses as of February 7, 2008. Estimated SPAC equity excludes unrestricted cash on the balance sheet at close

IV. Summary

Investment Highlights

Well Positioned in Attractive Niche Market

- 4th largest provider in US home infusion marketplace
- Viewed as a "preferred" consolidator by independents
- Upside from drug pipeline and Medicare IV coverage

Highly Successful Business Strategy

- EBITDA margin highest amongst industry peers
- Margin improvement with leverage of scale and operating efficiencies

Favorable Organic Growth Trends

- \$5–\$6 billion industry with 6%–7% annual growth
- Cost containment, demographics, and patient preference are all drivers

Demonstrated Ability to Acquire and Integrate Acquisitions

- Successfully integrated 9 acquisitions, including Deaconess with \$128mm in 2007E revenue
- Team integrated over 70 acquisitions since 1995
- Highly fragmented industry

Talented and Experienced Managed Team

- Track record of success with American Homecare Supply, Air Products Healthcare and Critical Homecare Solutions
- Team has been consolidating homecare for the last 13 years

Financial Summary

<i>(\$ mm)</i>	PF Q1 2007A	Q1 2008A	\$ Change	% Change
Revenue	49.8	54.7	4.9	9.8%
Gross Profit	24.0	27.7	3.7	15.4%
EBITDA, Pre-Corporate 1	9.0	11.7	2.7	30.0%
EBITDA, Post-Corporate 1	8.2	10.2	2.0	24.4%
Capital Expenditures	0.9	0.5	(0.4)	(44.4)%
EBITDA less CapEx	7.3	9.7	2.4	32.9%
<i>% of Revenue</i>				
<i>Gross Margin</i>	48.2%	50.6%		
<i>EBITDA, Pre-Corporate 1</i>	18.1%	21.3%		
<i>Y-o-Y Growth, Net Revenue</i>		9.8%		

V. Questions & Answers
